-

10:46:19 AM

LFCR Stock News

LFCR - Lifecore Biomedical Inc

03/16/23 4:24 PM

Nasdaq : LFCR

Lifecore Biomedical Signs Term Sheet with Existing Long-Term Customer to Expand CDMO Relationship

Provides $10 million upfront cash commitment to Lifecore for infrastructure preparation and production capacity preparation Customer to provide reimbursement for up to $15 million in capital expenditures to expand capacity Contemplates negotiation of multi-year amendment to extend and expand

RHEA-AI

very positive

03/16/23 4:23 PM

Nasdaq : LFCR

Lifecore Biomedical Announces Intent to Explore Strategic Alternatives

Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the Board of Directors of the Company (the “Board”) intends to initiate a process to

RHEA-AI

neutral

03/16/23 4:21 PM

Nasdaq : LFCR

earnings

Lifecore Biomedical Reports Second Quarter Fiscal Year 2023 Results

Company Announces Intention to Explore Strategic Alternatives Signs Term Sheet with Key Customer to Materially Expand Commercial Relationship Expands Development Pipeline from 24 to 25 Active Projects as of Fiscal Second Quarter-end Subsequently Transitioned Three Projects to Commercialization with

RHEA-AI

negative

02/07/23 4:30 PM

Nasdaq : LFCR

Lifecore Biomedical Announces Sale of Curation Foods’ Avocado Products Business

Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has completed the sale of its Curation Food’s

RHEA-AI

neutral

01/11/23 4:35 PM

Nasdaq : LFCR

Lifecore Biomedical Receives Notice from Nasdaq Regarding Delayed Quarterly Report

Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), announced today that it received a notice (“Notice”) on January 11, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that the Company is not in

RHEA-AI

neutral

01/09/23 4:05 PM

Nasdaq : LFCR

Lifecore Biomedical Raises Capital with Private Placement of Convertible Preferred Stock; Amends Credit Facilities

$38.75 million Private Placement of Series A Convertible Preferred Stock to Support Working Capital and Capital Expenditures While Pursuing Ongoing Divestment Process of non-CDMO Assets Credit Facilities Amended to Increase Liquidity and Provide Financial Covenant Relief Nathaniel Calloway, PhD and

RHEA-AI

neutral

11/25/22 4:50 PM

Nasdaq : LFCR

Lifecore Biomedical Raises Capital for Growth with Existing Stockholder

Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced the closing of a

RHEA-AI

neutral

11/14/22 9:01 AM

Nasdaq : LFCR, LNDC

Lifecore Biomedical Announces Completion of Corporate Name Change

Lifecore Biomedical, Inc. (“Lifecore” or the

RHEA-AI

neutral

LFCR Data

IndustryPlastics Material and Resin Manufacturing
Websitewww.landec.com
CeoAlbert Bolles
Security nameLifecore Biomedical Inc
Issue typecs
SectorManufacturing
Sic code2033
Employees689
Address5201 Great America Pkwy Ste 232
StateCalifornia
CitySanta Clara
Zip95054-1126
CountryUS
Phone16503061650

About Lifecore Biomedical Inc

Landec Corporation is a leading innovator of diversified health and wellness solutions with two operating businesses: Curation Foods, Inc. and Lifecore Biomedical, Inc.Landec designs, develops, manufactures and sells products for the food and biopharmaceutical industry. Curation Foods is focused on innovating and distributing plant-based foods with 100% clean ingredients to retail, club and foodservice channels throughout North America. Curation Foods is able to maximize product freshness through its geographically dispersed family of growers, refrigerated supply chain and patented BreatheWay® packaging technology. Curation Foods brands include Eat Smart® fresh packaged vegetables and salads, O Olive Oil & Vinegar® premium artisan products and Yucatan® and Cabo Fresh® avocado products. Lifecore Biomedical is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes and vials. As a leading manufacturer of premium, injectable grade Hyaluronic Acid, Lifecore brings 35 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market.